<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041231</url>
  </required_header>
  <id_info>
    <org_study_id>133</org_study_id>
    <nct_id>NCT05041231</nct_id>
  </id_info>
  <brief_title>Effects of Using Custom Photobiomodulation Therapy for the Treatment of Osteoarthritis of the Fingers and Rhizarthrosis</brief_title>
  <official_title>Effects of Using Custom Photobiomodulation Therapy for the Treatment of Osteoarthritis of the Fingers and Rhizarthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vita Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tegos S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vita Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthrosis (OA), a multifactorial degenerative process, is responsible for joint pain and&#xD;
      functional limitation. In the hand, more specifically in the proximal and distal&#xD;
      interphalangeal joints of the fingers, it is one of the sites of greatest manifestation of&#xD;
      the disease. Numerous treatments, whether drug, rehabilitation or surgery, have been proposed&#xD;
      with the aim of both interrupting the natural evolution of the disease and alleviating or&#xD;
      stopping the symptoms. This study aims to evaluate the effectiveness of personalized&#xD;
      Photobiomodulation Therapy (PBT) with regard to alleviating symptoms and improving the&#xD;
      quality of life of these patients with the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Pain at</measure>
    <time_frame>4 weeks and 2 months</time_frame>
    <description>Visual analogue scale for pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Arm, Shoulder and Hand Disability</measure>
    <time_frame>4 weeks and 2 months</time_frame>
    <description>The Disabilities of the Arm, Shoulder and Hand Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Hand grip</measure>
    <time_frame>4 weeks and 2 months</time_frame>
    <description>Hand grip strenght measured by Digital Hand Dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Pinch force</measure>
    <time_frame>4 weeks and 2 months</time_frame>
    <description>Pulp to pulp (pinch) force</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to recommend the treatment</measure>
    <time_frame>4 weeks and 2 months</time_frame>
    <description>Net Promoter Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Hand Disability</measure>
    <time_frame>4 weeks and 2 months</time_frame>
    <description>Brief Michigan questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Osteoarthritis Finger</condition>
  <condition>Osteoarthritis Hand</condition>
  <condition>Osteoarthritis Both Hands</condition>
  <arm_group>
    <arm_group_label>Sham (group A)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment procedure performed with the device that will not provide the bioactive light (laser)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBT (group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment procedure performed with the device that will provide the bioactive light (laser)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photobiomodulation therapy (PBT)</intervention_name>
    <description>Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.&#xD;
The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm).</description>
    <arm_group_label>PBT (group B)</arm_group_label>
    <other_name>Laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Photobiomodulation therapy (Sham PBT)</intervention_name>
    <description>Similar to active PBT, however, the device will not provide the active electromagnetic waves)</description>
    <arm_group_label>Sham (group A)</arm_group_label>
    <other_name>Sham Laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical and radiological diagnosis of OA of the fingers of the hand and Rizarthrosis&#xD;
&#xD;
          -  Patients with pain for at least 3 months&#xD;
&#xD;
          -  Patients undergoing treatment and rehabilitation for finger OA and rhizarthrosis&#xD;
&#xD;
          -  Patient with good understanding of the Portuguese language who agrees to participate&#xD;
             and sign the ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Posttraumatic arthritic changes&#xD;
&#xD;
          -  Systemic inflammatory arthritis (Rheumatoid Arthritis, Lupus Erythematosus,&#xD;
             Psoriasis…)&#xD;
&#xD;
          -  Patients with local or systemic, acute or chronic infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mateus Saito, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director Instituto Vita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernardo Althoff, MD</last_name>
    <phone>551131238482</phone>
    <email>bernardoalthoff@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Marchi, PhD</last_name>
    <phone>551131238482</phone>
    <email>luis.marchi@institutovita.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Vita</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05653-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Marchi, PhD</last_name>
      <phone>551131238482</phone>
      <email>luis.marchi@institutovita.org.br</email>
    </contact>
    <investigator>
      <last_name>Mateus Saito, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardo Althoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

